title: Inhibitory potential of Chlorella vulgaris (E-25) on mouse skin papillomagenesis and xenobiotic detoxication system.
abstract: The present study assesses the modulatory potential of Chlorella vulgaris (E-25) on murine skin papillomagenesis, and the role of xenobiotic detoxication system in modulating the papillomagenesis pattern. Topical application of E-25 (500 mg/kg b.w./day) during peri-, post- or peri- and post-initiational stages of 7,12-dimethylbenz [a] anthracene (DMBA)-induced papillomagenesis, significantly modulated the a) tumor burden to 5.00, 4.33 and 3.94 (positive control value: 5.88 b) cumulative number of papillomas to 90, 78 and 67 (positive control value: 106); and c) percent incidence of mice bearing papillomas to 94, 90 and 89 respectively (positive control value: 100). E-25 treatment alone or during peri-, post- or peri- and post-initiational stages significantly elevated the sulfhydryl (-SH) and glutathlone S-transferase (GST) levels in the liver and skin tissues. However, the levels of microsomal cytochrome b5 (Cyt. b5) and cytochrome P-450 (Cyt. P-450) were not appreciably modulated by the topical treatment of E-25. The results suggest the chemopreventive potential of E-25 during peri-, post- or peri- and post-initiational stages of murine skin papillomagenesis. The possible significance of xenobiotic detoxication system in modulating the papillomagenesis pattern is discussed.
authors.affiliation: Human Genetics Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
authors.forename: A
authors.initials: A
authors.lastname: Singh
authors.forename: S P
authors.initials: SP
authors.lastname: Singh
authors.forename: R
authors.initials: R
authors.lastname: Bamezai
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000287:Administration, Topical; D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002708:Chlorella / Q000737:chemistry / Q000502:physiology*; D003436:Croton Oil; D003577:Cytochrome P-450 Enzyme System / Q000032:analysis; D015786:Cytochromes b5 / Q000032:analysis; D018450:Disease Progression; D004334:Drug Administration Schedule; D005982:Glutathione Transferase / Q000032:analysis; D008658:Inactivation, Metabolic / Q000502:physiology*; D008099:Liver / Q000201:enzymology; D008297:Male; D051379:Mice; D008862:Microsomes, Liver / Q000201:enzymology; D010212:Papilloma / Q000139:chemically induced / Q000517:prevention & control*; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D012867:Skin / Q000201:enzymology; D012878:Skin Neoplasms / Q000139:chemically induced / Q000517:prevention & control*; D015262:Xenobiotics / Q000493:pharmacokinetics*
chemical_list: D016588:Anticarcinogenic Agents; D010936:Plant Extracts; D015262:Xenobiotics; D015127:9,10-Dimethyl-1,2-benzanthracene; D003436:Croton Oil; D015786:Cytochromes b5; D003577:Cytochrome P-450 Enzyme System; D005982:Glutathione Transferase